NCT07107633

A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor.

A Multicenter, Open-access, Self-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mTc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignancies.

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd. · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the effectiveness of technetium \[99mTc\]-H7ND injection in the diagnosis of peritoneal metastasis of gastrointestinal malignant tumor. Objective: To evaluate the safety of technetium \[99mTc\]-H7ND injection in the diagnosis of peritoneal metastasis of gastrointestinal malignant tumor. Objective: To explore the diagnostic threshold of technetium \[99mTc\]-H7ND injection for peritoneal metastasis of gastrointestinal malignant tumor.

Conditions

• Solid Tumor
• Peritoneal Metastasis

Interventions

Type	Name	Description
DRUG	Technetium [99mTc]-H7ND injection	Technetium \[99mTc\]-H7ND injection is a radiolabeled fibroblast activation protein inhibitor

Timeline

• Start date: 2025-03-12
• Primary completion: 2025-09-01
• Completion: 2025-09-01
• First posted: 2025-08-06
• Last updated: 2025-08-06

Locations

1 site across 1 country: China